MedTrace Logo

Omega 3, Leucine, Probiotic Lactobacillus Paracasei PS23 on Muscle Mass in Sarcopenic Subjects

NCT04702087 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 54

Last updated 2021-10-05

No results posted yet for this study

Summary

The purpose of the study is to evaluate the effect of supplementation with a nutritional blend based on Omega 3 fatty acids, the probiotic leucine Lactobacillus paracasei PS23 (OLEP), on muscle mass recovery in sarcopenic patients.

Conditions

Interventions

DIETARY_SUPPLEMENT

OLEP

omega 3 (500 mg), leucine (2,5 g), probiotic Lactobacillus paracasei PS23

COMBINATION_PRODUCT

Placebo

Isocaloric formula

Sponsors & Collaborators

  • Abiogen Pharma

    collaborator INDUSTRY

  • Azienda di Servizi alla Persona di Pavia

    lead OTHER

Principal Investigators

  • Mariangela Rondanelli · Fondazione Casemiro Mondino

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-01-22
Primary Completion
2021-01-30
Completion
2022-12-31

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04702087 on ClinicalTrials.gov